Biotech Company Opthea Aims To Raise $160M In US IPO
Opthea Limited, a biotechnology company focussed on retinal diseases, announced Sunday it is seeking an initial public offering in the United States.
What Happened: The Melbourne Australia-based biopharmaceutical company will offer American Depositary Shares each of which will represent eight of the company’s ordinary shares.